QUARTERLY FINANCIAL DATA (UNAUDITED)

The unaudited quarterly financial data for the last two fiscal years was as follows (in thousands, except per share data):



	Quarter Ended
	December 31,		September 30,		June 30,		March 31,
2018:
Total revenues ⁽¹⁾	$	228,602	$	225,397	$	186,108	$	213,719
Gross profit ⁽²⁾	$	168,873	$	155,586	$	139,839	$	128,633
Income from operations	$	111,602	$	125,176	$	85,770	$	116,307
Net income	$	360,089	$	126,630	$	87,494	$	115,857
Net income per share, basic	$	1.20	$	0.42	$	0.29	$	0.39
Net income per share, diluted	$	1.15	$	0.41	$	0.28	$	0.37
2017:
Total revenues	$	120,072	$	152,510	$	99,008	$	80,887
Gross profit ⁽²⁾	$	91,520	$	91,758	$	84,990	$	65,674
Income from operations	$	37,431	$	81,180	$	27,113	$	20,186
Net income	$	38,489	$	81,382	$	17,656	$	16,700
Net income per share, basic	$	0.13	$	0.28	$	0.06	$	0.06
Net income per share, diluted	$	0.12	$	0.26	$	0.06	$	0.05

____________________

(1)

Total revenues for the three months ended March 31, 2018 have been adjusted to reflect the reclassification of the $1.4 million profit related to the profit sharing arrangement with Genentech for the commercialization of COTELLIC. For three months ended March 31, 2018, the net profit had been classified as Selling, general and administrative expenses as we were expecting an overall loss for the year ended December 31, 2018. During the three months ended June 30, 2018, we determined that the U.S. commercialization of COTELLIC would result in a profit for the year ended December 31, 2018 and therefore, we reclassified the profit for the three months ended March 31, 2018 from Selling, general and administrative expenses to Collaboration revenues to be consistent with presentation for the three and six months ended June 30, 2018. See “Note 3. Collaboration Agreements” for more information on our collaboration agreement with Genentech.


(2)	Gross profit is computed as Net product revenues less Cost of goods sold.